New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
16:16 EDTGHDXGenomic Health sees FY13 EPS ex-items 48c-68c, consensus 28c
Sees FY13 revenue $258M-$266M, consensus $262.4M. The company said, "In 2013, we plan to continue to invest in near-term opportunities to expand our global breast and colon cancer businesses in order to drive top-line revenue growth, and in our prostate cancer launch to build long-term value, and expect losses in the first and second quarters." Sees FY13 GAAP EPS (12c)-8c and non-GAAP basic EPS, excluding stock compensation expense, 48c-68c.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
08:05 EDTGHDXGenomic Health to present positive results from nine studies of Oncotype DX
Genomic Health announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology, or ESMO, 2014 Congress in Madrid, September 26 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville. This new study demonstrates the test's ability to predict a rise in prostate-specific antigen, or PSA, following surgery and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use